Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 17

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 17
---
5, and does not include the following as of that date:

| ● | 23,853,289 common shares issuable upon the exercise                                                                                                                                                                                                             
 of warrants outstanding as of such date, at exercise prices ranging from $0.10 to $243.75, all of which were vested as of such date;                                                                                                                            |
| ● | 5,521 common shares issuable upon the exercise of options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average exercise price of $429.24, of which 5,513 were vested as of such date; and |
| ● | 1,251 common shares issuable upon the exercise of restricted share units issued to consultants under consulting agreements.                                                                                                                                     |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of the warrants or options described above. See “Description of Share Capital” for additional information.

12 RISK FACTORS Investing in our Common Shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the other information set forth in this prospectus, including the consolidated financial statements and the related notes included elsewhere in this prospectus, before purchasing our Common Shares. If any of the following risks actually occurs, our business, financial condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our Common Shares would likely decline and you might lose all or part of your investment. Risks Related to Ownership of Our Common Shares and this Offering We may be or may become classified as a passive foreign investment company. If we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences as a result. Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares) and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of